The Role of the Key Differentially Mutated Gene FGFR3 in the Immune Microenvironment of Bladder Cancer

Figure 2

Correlation analysis of immune score and stromal score with survival and clinicopathological characteristics in bladder cancer cases. (a–c) Kaplan-Meier survival analysis of bladder cancer cases by comparing them with the median to determine high and low scores in immune score, stromal score, and estimate score, which was tested by the log-rank test. (d–f) Distribution of immune score, stromal score, and estimate score at different stages of cancer, which was tested by the Kruskal-Wallis rank-sum test. (g–i) Distribution of the three scores in T staging, which was tested by the Kruskal-Wallis rank-sum test. (j–l) Distribution of the three scores in N staging, which was tested by the Kruskal-Wallis rank-sum test. (m–o) Distribution of the three scores in M staging, which was tested by the Wilcoxon rank-sum test.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

(m)

(n)

(o)